VEGFA and neoplasm: Bevacizumab is a humanized monoclonal antibody against VEGF-A and aflibercept (VEGF-Trap) is a soluble fusion protein for the extracellular domain of VEGFR-1 and VEGFR-2 and the Fc region of immunoglobulin G. These agents neutralize VEGF-A, preventing tumor angiogenesis.